Firebrick Pharma Investor Update
Key points
- Nasodine Nasal Spray launched in USA and Singapore
- Approval in Indonesia and potential Philippines launch
- Expansion into new markets and product lines
Full summary
Firebrick Pharma Ltd. provides an update on the commercial progress of Nasodine Nasal Spray, a nasal antiseptic developed to combat airborne viruses and bacteria. The product has been launched online in the USA in April 2024 and in Singapore in June 2024. Approval in Indonesia, the largest market in Southeast Asia, was announced in March 2026. The company is also applying for approval in the Philippines and expects to be approved or on sale in 10 markets within three years. Manufacturing sites are located in Australia, the Philippines, and the USA. A second product, Nasodine Throat Spray, was launched in Singapore in January 2026, with a potential roll-out in the US later this year. A third Nasodine product is expected in 2026. The company faces regulatory challenges in markets like Australia, where Nasodine is classified as a medicine, but sees potential in the US and Southeast Asia, where it is classified as an antiseptic.
Summary generated by a large language model. Please interpret with care.